On September 3, 2025, Artelo Biosciences, Inc. announced promising interim results for its ART27.13 treatment for cancer anorexia-cachexia syndrome, showing a 6.38% weight gain compared to a 5.42% loss in the placebo group. The company plans to pursue external partnerships instead of a Phase 3 trial to maximize shareholder value.